Key result
Higher circulating adropin is linked to greater systolic blood pressure variability in older adults.
Why the study?
Does higher circulating adropin predict greater systolic blood pressure variability in older adults?
Cohort
Does higher circulating adropin predict greater systolic blood pressure variability in older adults?
Answers are grounded in this paper and cite their sources.
Circulating adropin levels may serve as a novel biomarker for predicting blood pressure variability and identifying older adults at risk for poor BP control.
This study identifies circulating levels of the hepatokine adropin as a novel biomarker of blood pressure (BP) variability in older adults. Using longitudinal data from the Multidomain Alzheimer Prevention Trial, we show that higher adropin levels predict greater systolic BP variability, particularly in participants receiving antihypertensive therapy. These findings link a hepatokine with cardiovascular risk and suggest that adropin measurement may improve stratification of individuals at risk for poor BP control and treatment resistance.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2025) conducted a cohort in Blood pressure variability. High circulating adropin levels was evaluated on Systolic blood pressure variability. Higher circulating adropin levels predicted greater long-term systolic blood pressure variability in older adults, particularly among those receiving antihypertensive therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: